Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sites

▴ Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sites
The Bharat Biotech, which is into developing Covaxin - a vaccine candidate for COVID-19, on Friday said that it will now be conducting Phase III trials

The Bharat Biotech, which is into developing Covaxin - a vaccine candidate for COVID-19, on Friday said that it will now be conducting Phase III trials in 25 centres across the country with a total of 26,000 people participating in the trials. Bharat Biotech successfully completed interim analysis of Phase I and II trials of Covaxin. 

According to report, the Drug Controller General of India (DCGI) has also given Bharat Biotech the permission to go ahead with the Phase III trials after successful completion of Phase I and Phase II clinical trials.

"After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of Covaxin, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India," the vaccine maker said in an official communication.

An expert panel at the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission for conducting phase 3 clinical trials of its indigenously developed COVID-19 vaccine with certain conditions.

The phase 3 clinical trial application has proposed a dose of 0.5 ml on day 0 and 28.

Story Source- www.abplive.in 

Tags : #BharatBiotech #LatestNewsonBharatBiotech24thOct #LatestPharmaNews24thOct #LatestCOVIDNews24thOct #LatestNewsonCOVIDVaccine24thOct #DrugControllerGeneralofIndia

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Hon'ble Prime Minister of India, Shri Narendra Modiji's inspiring presence at the Zydus Biotech ParkNovember 30, 2020
Britain secures additional 2 million doses of Moderna's COVID-19 vaccineNovember 30, 2020
Dupixent approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitisNovember 30, 2020
DRDO increases number of ICU beds to 500 in Sardar Vallabhbhai Patel COVID Hospital at Delhi CanttNovember 30, 2020
COVID-19 recovery rate in country improves to 93.81 pctNovember 30, 2020
Gestational diabetes - Will it affect my baby? November 30, 2020
PM to interact with 3 teams involved in developing COVID-19 vaccine.November 30, 2020
Uttarakhand govt makes Covid-19 test mandatory for entry November 30, 2020
Unichem gets US FDA approval for Atenolol and Chlorthalidone TabletsNovember 30, 2020
Dr Reddy’s buys select anti-allergy brands from Glenmark in Russia and other CIS countries November 30, 2020
Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development November 30, 2020
71% of the daily fatalities contributed by eight States/UT - Delhi, Maharashtra, WB, Haryana, Punjab, Kerala, Uttar Pradesh and RajasthanNovember 30, 2020
Rajasthan govt decides to close schools, colleges, cinema, entertainment parks in state till Dec 31 November 30, 2020
India Covid-19 News Updates :Nov 29, 2020November 29, 2020
PM congratulates scientists on progress of Covid19 vaccine at Bharat BiotechNovember 28, 2020
COVID-19 recovery rate in country stands at 93.68 percent.November 28, 2020
Vertex Pharma received European Commission Approval for SYMKEVI With KALYDECONovember 28, 2020
Co-Diagnostics JV CoSara Diagnostics receives clearance from CDSCO for COVID-19 2-Gene Multiplex TestNovember 28, 2020
SAL unveils new pharma and perishable facilities in Riyadh in time for COVID vaccines distributionNovember 28, 2020
Number of Covid tests per million population in country cross one lakh markNovember 28, 2020